Last reviewed · How we verify
TVAV-008
TVAV-008 is a small molecule that targets the S1P1 receptor.
TVAV-008 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | TVAV-008 |
|---|---|
| Sponsor | Grand Theravac Life Sciences (Nanjing) Co., Ltd. |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to the S1P1 receptor, TVAV-008 modulates sphingosine-1-phosphate signaling, which plays a crucial role in immune cell trafficking and lymphocyte egress from lymphoid organs.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |